Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a sedative help rebuilt tissue survive after cancer surgery?

NCT ID NCT06993740

Disease control Sponsor: Dharmais National Cancer Center Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether giving the sedative dexmedetomidine during and after reconstructive microsurgery can help transplanted tissue (flaps) survive better in cancer patients. The study will compare flap health at 48 hours after surgery in patients receiving dexmedetomidine versus a placebo, and will also measure blood markers related to inflammation, blood clotting, and tissue repair. The goal is to see if this drug can reduce complications like flap failure by protecting blood vessels and improving blood flow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexmedetomidine, a sedative given intravenously during and after surgery
What this could lead to
If effective, this could improve the success of reconstructive surgery in cancer patients, reducing the risk of flap failure and the need for additional operations.
What could go wrong
This is a small, early-stage trial, and the results may not apply to all patients. Dexmedetomidine can cause low blood pressure or slow heart rate, and its benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (aged 18-65 years) diagnosed with cancer who are scheduled to undergo microsurgical flap reconstruction. 2. Patients within the age range of 18 to 65 years at the time of enrollment. 3. Patients who provide written informed consent to participate in the study. Exclusion Criteria: 1. Patients with a history of uncontrolled diabetes mellitus. 2. Patients diagnosed with chronic kidney disease. 3. Patients with known liver failure. 4. Patients receiving corticosteroid therapy prior to surgery. 5. Patients with uncontrolled hypertension. 6. Patients with a history of chemotherapy or radiotherapy prior to surgery. 7. Patients diagnosed with preoperative sepsis. 8. Patients requiring perioperative vasopressor support. 9. Patients with a history of prior surgery in the same operative field. 10. Patients who decline to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anesthesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Inflammation inflammatory disease limb ischemia thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anesthesia Flap failure risk factors Flap ischemia Flap monitoring Flap necrosis Glycocalyx Inflammation Microsurgery Oxidative stress Surgery Thrombosis

Contacts and locations

Locations

  • Dharmais National Cancer Center Hospital

    Jakarta, DKI Jakarta, 11420, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.